AI in Drug Trials, Pfizer's Innovations, and NVIDIA's CoreWeave Partnership
In this episode, Bob introduces the role of AI in drug development, particularly its impact on streamlining clinical trials. The discussion then shifts to Pfizer's recent innovations in AI, which have reportedly reduced the time to market for new drugs. Bob highlights Recursive's advancements in self-improving AI systems and their recent funding achievements. Attention is given to NVIDIA's collaboration and investment in CoreWeave's AI factories, which aim to bolster AI infrastructure. The episode concludes with closing remarks and an outlook on future developments in AI, emphasizing the importance of these advancements in shaping the industry.
Key Points
- AI is revolutionizing the pharmaceutical industry by accelerating drug trials and streamlining regulatory submissions, potentially reducing the time to market by up to 30 percent.
- Start-ups like Ricursive Intelligence are pioneering self-improving AI systems that could lead to continuous advancements in technology, driven by a recursive loop of improvement.
- NVIDIA and CoreWeave's collaboration to build AI factories represents a significant investment in the future of AI infrastructure, aiming to meet the growing global demand for computational power.
Chapters
| 0:00 | |
| 1:13 | |
| 2:21 | |
| 3:50 | |
| 5:43 |
Transcript
Loading transcript...
- / -